MX2018001435A - Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. - Google Patents
Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.Info
- Publication number
- MX2018001435A MX2018001435A MX2018001435A MX2018001435A MX2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A
- Authority
- MX
- Mexico
- Prior art keywords
- lennox
- fenfluramine
- syndrome
- treatment methods
- gastaut syndrome
- Prior art date
Links
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 title abstract 6
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001582 fenfluramine Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paper (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método de tratamiento y/o prevención de síntomas del síndrome de Lennox-Gastaut (LGS) también conocido como Síndrome de Lennox en un paciente, tal como un paciente previamente diagnosticado con el Síndrome de Lennox, mediante la administración de una dosis efectiva de fenfluramina o sus sales farmacéuticamente aceptables a dicho paciente. Los pacientes con Síndrome de Lennox son tratados con una dosis preferida de menos de aproximadamente 2.0 a aproximadamente 0.01 mg / kg / día.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209090P | 2015-08-24 | 2015-08-24 | |
| PCT/US2016/048470 WO2017035267A1 (en) | 2015-08-24 | 2016-08-24 | Methods of treating lennox-gastaut syndrome using fenfluramine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001435A true MX2018001435A (es) | 2018-04-20 |
| MX389927B MX389927B (es) | 2025-03-20 |
Family
ID=58101064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001435A MX389927B (es) | 2015-08-24 | 2016-08-24 | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170056344A1 (es) |
| EP (2) | EP3340971B1 (es) |
| JP (1) | JP6895949B2 (es) |
| KR (3) | KR102615486B1 (es) |
| CN (3) | CN108135865A (es) |
| AU (1) | AU2016312526B2 (es) |
| BR (1) | BR112018002046A2 (es) |
| CA (1) | CA2993665C (es) |
| DK (1) | DK3340971T3 (es) |
| ES (1) | ES2979034T3 (es) |
| FI (1) | FI3340971T3 (es) |
| HR (1) | HRP20240508T1 (es) |
| HU (1) | HUE066912T2 (es) |
| IL (1) | IL257276B (es) |
| LT (1) | LT3340971T (es) |
| MX (1) | MX389927B (es) |
| PL (1) | PL3340971T3 (es) |
| PT (1) | PT3340971T (es) |
| RU (1) | RU2740919C2 (es) |
| SI (1) | SI3340971T1 (es) |
| WO (1) | WO2017035267A1 (es) |
| ZA (1) | ZA201800499B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10647465B2 (en) | 2010-11-12 | 2020-05-12 | Niagara Bottling, Llc | Perform extended finish for processing light weight ecologically beneficial bottles |
| ES2695301T3 (es) | 2010-11-12 | 2019-01-03 | Niagara Bottling Llc | Acabado extendido de preforma para procesar botellas de peso ligero |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| CA3032996C (en) | 2016-08-24 | 2025-05-06 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| US20180092864A1 (en) * | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| BR112019023483A2 (pt) * | 2017-05-09 | 2020-06-30 | Zogenix International Limited | composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose |
| US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| US10682317B2 (en) * | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| WO2019241005A1 (en) | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| EP3820459A1 (en) * | 2018-07-10 | 2021-05-19 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
| US11597556B2 (en) | 2018-07-30 | 2023-03-07 | Niagara Bottling, Llc | Container preform with tamper evidence finish portion |
| AU2019384963B2 (en) * | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| EP3930841A4 (en) * | 2019-02-25 | 2022-11-30 | Zogenix International Limited | A formulation for improving seizure control |
| EP4031114A1 (en) * | 2019-09-17 | 2022-07-27 | Zogenix International Limited | Methods of treating epileptic patients with fenfluramine |
| US20210299064A1 (en) * | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
| GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
| IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
| JP2008542237A (ja) * | 2005-05-25 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トピラメートの小児科用製剤 |
| US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
| GB0515090D0 (en) * | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| EP2350010B1 (en) * | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AR079862A1 (es) * | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
| AU2011243947A1 (en) * | 2010-04-23 | 2012-12-06 | Piramal Enterprises Limited | Nitric oxide releasing prodrugs of therapeutic agents |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| ES2813450T3 (es) | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
| KR102245345B1 (ko) | 2014-09-29 | 2021-04-28 | 조게닉스 인터내셔널 리미티드 | 의약품 배포 제어를 위한 제어 시스템 |
-
2016
- 2016-08-24 PT PT168400620T patent/PT3340971T/pt unknown
- 2016-08-24 BR BR112018002046A patent/BR112018002046A2/pt not_active Application Discontinuation
- 2016-08-24 FI FIEP16840062.0T patent/FI3340971T3/fi active
- 2016-08-24 SI SI201631816T patent/SI3340971T1/sl unknown
- 2016-08-24 JP JP2018510511A patent/JP6895949B2/ja active Active
- 2016-08-24 RU RU2018108202A patent/RU2740919C2/ru active
- 2016-08-24 AU AU2016312526A patent/AU2016312526B2/en active Active
- 2016-08-24 MX MX2018001435A patent/MX389927B/es unknown
- 2016-08-24 CN CN201680049517.7A patent/CN108135865A/zh active Pending
- 2016-08-24 HR HRP20240508TT patent/HRP20240508T1/hr unknown
- 2016-08-24 KR KR1020227045101A patent/KR102615486B1/ko active Active
- 2016-08-24 CN CN202210746238.3A patent/CN115192575A/zh active Pending
- 2016-08-24 CN CN202211037242.9A patent/CN115350168A/zh active Pending
- 2016-08-24 PL PL16840062.0T patent/PL3340971T3/pl unknown
- 2016-08-24 US US15/246,346 patent/US20170056344A1/en not_active Abandoned
- 2016-08-24 ES ES16840062T patent/ES2979034T3/es active Active
- 2016-08-24 EP EP16840062.0A patent/EP3340971B1/en active Active
- 2016-08-24 CA CA2993665A patent/CA2993665C/en active Active
- 2016-08-24 KR KR1020227005011A patent/KR102481631B1/ko active Active
- 2016-08-24 HU HUE16840062A patent/HUE066912T2/hu unknown
- 2016-08-24 DK DK16840062.0T patent/DK3340971T3/da active
- 2016-08-24 LT LTEPPCT/US2016/048470T patent/LT3340971T/lt unknown
- 2016-08-24 KR KR1020187005840A patent/KR20180054584A/ko not_active Ceased
- 2016-08-24 EP EP24161855.2A patent/EP4397372A3/en active Pending
- 2016-08-24 WO PCT/US2016/048470 patent/WO2017035267A1/en not_active Ceased
-
2018
- 2018-01-24 ZA ZA2018/00499A patent/ZA201800499B/en unknown
- 2018-01-31 IL IL257276A patent/IL257276B/en unknown
-
2020
- 2020-05-01 US US16/864,955 patent/US20200253895A1/en active Pending
-
2024
- 2024-01-19 US US18/418,121 patent/US20240245631A1/en active Pending
- 2024-01-19 US US18/418,133 patent/US20240238222A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2018002906A (es) | Metodos de tratamiento de trastornos del desarrollo con pipradrol. | |
| EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
| MX366497B (es) | Cepas de bacteriófagos capaces de producir una infección lítica en una cepa de escherichia coli adherente-invasiva y su uso para el tratamiento de enfermedades inflamatorias intestinales. | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| BR112016029437A2 (pt) | métodos para tratamento e prevenção de doenças de instabilidade vascular | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| GB2537783A (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
| MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| CA3069989C (en) | METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG | |
| EA202190294A1 (ru) | Комбинированная терапия для лечения рака |